Karyopharm Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 2, 2026, 9:21 a.m. ETView on SEC.gov Our explainer
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedKaryopharm Therapeutics Files Chapter 11 and Signs Restructuring Support Agreement for Merger with Ayrmid; Common Stock Expected to Have No Value
8-KOct. 22, 2026, 4:15 p.m. ETView on SEC.gov
Other events
AI summary, unreviewedKaryopharm Therapeutics extends forbearance period on indentures to November 1, 2026
8-KOct. 14, 2026, 7:30 a.m. ETView on SEC.gov
Other events
AI summary, unreviewedKaryopharm Therapeutics extends forbearance period on indentures to October 22, 2026
8-KSept. 18, 2026, 4:05 p.m. ETView on SEC.gov
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
8-KSept. 11, 2026, 7:45 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Triggering events accelerating an obligation · Unregistered sales of equity securities · Other events · Financial statements and exhibits
8-KAug. 31, 2026, 8:08 a.m. ETView on SEC.gov
Other events
8-KAug. 13, 2026, 7:37 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KJuly 31, 2026, 8:30 a.m. ETView on SEC.gov
Other events